171 related articles for article (PubMed ID: 36215514)
21. Pretargeted radioimmunotherapy with α-particle emitting radionuclides.
Lindegren S; Frost SH
Curr Radiopharm; 2011 Jul; 4(3):248-60. PubMed ID: 22201711
[TBL] [Abstract][Full Text] [Related]
22. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
23. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
24. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
25. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788
[TBL] [Abstract][Full Text] [Related]
26. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
27. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
Membreno R; Keinänen OM; Cook BE; Tully KM; Fung KC; Lewis JS; Zeglis BM
Mol Pharm; 2019 May; 16(5):2259-2263. PubMed ID: 30912951
[TBL] [Abstract][Full Text] [Related]
28. Pretargeted Imaging and Therapy.
Altai M; Membreno R; Cook B; Tolmachev V; Zeglis BM
J Nucl Med; 2017 Oct; 58(10):1553-1559. PubMed ID: 28687600
[TBL] [Abstract][Full Text] [Related]
29. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
30. Harnessing
Keinänen O; Fung K; Brennan JM; Zia N; Harris M; van Dam E; Biggin C; Hedt A; Stoner J; Donnelly PS; Lewis JS; Zeglis BM
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28316-28327. PubMed ID: 33106429
[TBL] [Abstract][Full Text] [Related]
31. Pretargeted Nuclear Imaging and Radioimmunotherapy Based on the Inverse Electron-Demand Diels-Alder Reaction and Key Factors in the Pretargeted Synthetic Design.
Qiu L; Mao W; Yin H; Tan H; Cheng D; Shi H
Contrast Media Mol Imaging; 2019; 2019():9182476. PubMed ID: 31531006
[TBL] [Abstract][Full Text] [Related]
32. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry.
van de Watering FC; Rijpkema M; Robillard M; Oyen WJ; Boerman OC
Front Med (Lausanne); 2014; 1():44. PubMed ID: 25593917
[TBL] [Abstract][Full Text] [Related]
33. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
[TBL] [Abstract][Full Text] [Related]
35. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
[TBL] [Abstract][Full Text] [Related]
36. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
37. An
Cheal SM; Patel M; Yang G; Veach D; Xu H; Guo HF; Zanzonico PB; Axworthy DB; Cheung NV; Ouerfelli O; Larson SM
Bioconjug Chem; 2020 Mar; 31(3):501-506. PubMed ID: 31891487
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
39. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
Orcutt KD; Slusarczyk AL; Cieslewicz M; Ruiz-Yi B; Bhushan KR; Frangioni JV; Wittrup KD
Nucl Med Biol; 2011 Feb; 38(2):223-33. PubMed ID: 21315278
[TBL] [Abstract][Full Text] [Related]
40. New insights into the pretargeting approach to image and treat tumours.
Patra M; Zarschler K; Pietzsch HJ; Stephan H; Gasser G
Chem Soc Rev; 2016 Nov; 45(23):6415-6431. PubMed ID: 27722526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]